Literature DB >> 16619536

Effects of PRIMA-1 on wild-type L1210 cells expressing mutant p53 and drug-resistant L1210 cells lacking expression of p53: necrosis vs. apoptosis.

Ann H Cory1, Jianming Chen, Joseph G Cory.   

Abstract

The effects of PRIMA-1 on wild-type (WT) mouse leukemia L1210 cells and drug-resistant L1210 cells (Y8) were studied with respect to the induction of apoptosis and necrosis in these cell lines. The WT L1210 cells express mutant p53 while the Y8 L1210 cells do not express p53 mRNA or protein, but do express WAF1/p21 and Gadd 45 mRNA's and proteins. It was found that, in response to treatment with PRIMA-1, the WT L1210 cells became necrotic with little apoptosis while the Y8 L1210 cells showed a much higher level of apoptosis than necrosis. Flavopiridol in combination with PRIMA-1 caused a synergistic increase in necrosis in the WT L1210 cells while LY 294002 in combination with PRIMA-1 caused a synergistic increase in apoptosis in the Y8 L1210 cells. These studies showed that PRIMA-1 had an effect not only on cells expressing mutant p53, but also on cells that do not express p53, suggesting that PRIMA-1 and PRIMA-1-like molecules have multiple sites of action independent of restoring p53 function and that these can interact with other signaling pathways involving CDK's and PI3 kinases.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16619536

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  6 in total

1.  Antiproliferative activities of halogenated thieno[3,2-d]pyrimidines.

Authors:  Kartik W Temburnikar; Sarah C Zimmermann; Nathaniel T Kim; Christina R Ross; Christopher Gelbmann; Christine E Salomon; Gerald M Wilson; Jan Balzarini; Katherine L Seley-Radtke
Journal:  Bioorg Med Chem       Date:  2014-03-03       Impact factor: 3.641

2.  Induction of apoptosis promoted by Bang52; a small molecule that downregulates Bcl-x(L).

Authors:  Matteo Rossi; Jeong-Kyu Bang; Sharlyn Mazur; Jaclyn A Iera; Darren C Phillips; Gerard P Zambetti; Daniel H Appella
Journal:  Bioorg Med Chem Lett       Date:  2009-03-21       Impact factor: 2.823

Review 3.  Targeting of Mutant p53 and the Cellular Redox Balance by APR-246 as a Strategy for Efficient Cancer Therapy.

Authors:  Vladimir J N Bykov; Qiang Zhang; Meiqiongzi Zhang; Sophia Ceder; Lars Abrahmsen; Klas G Wiman
Journal:  Front Oncol       Date:  2016-02-03       Impact factor: 6.244

4.  Sensitivity to PRIMA-1MET is associated with decreased MGMT in human glioblastoma cells and glioblastoma stem cells irrespective of p53 status.

Authors:  Mariia Patyka; Zeinab Sharifi; Kevin Petrecca; Jose Mansure; Bertrand Jean-Claude; Siham Sabri
Journal:  Oncotarget       Date:  2016-09-13

Review 5.  p53 and metabolism: from mechanism to therapeutics.

Authors:  Fernando M Simabuco; Mirian G Morale; Isadora C B Pavan; Ana P Morelli; Fernando R Silva; Rodrigo E Tamura
Journal:  Oncotarget       Date:  2018-05-04

6.  Small molecule MIRA-1 induces in vitro and in vivo anti-myeloma activity and synergizes with current anti-myeloma agents.

Authors:  M N Saha; Y Chen; M-H Chen; G Chen; H Chang
Journal:  Br J Cancer       Date:  2014-04-01       Impact factor: 7.640

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.